Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Surmodics, Inc. - Common Stock (NQ:SRDX)

27.09 +0.33 (+1.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 49,277
Open 27.17
Bid (Size) 26.50 (1)
Ask (Size) 28.17 (1)
Prev. Close 26.76
Today's Range 26.84 - 27.36
52wk Range 26.00 - 42.44
Shares Outstanding 14,134,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Earnings Scheduled For April 30, 2025
Via Benzinga

Performance

YTD
-31.7%
-31.7%
1 Month
-4.7%
-4.7%
3 Month
-21.8%
-21.8%
6 Month
-29.6%
-29.6%
1 Year
-16.5%
-16.5%

More News

Read More
A Look at Surmodics's Upcoming Earnings Report
Via Benzinga
Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30
From Surmodics, Inc.
Via Business Wire
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon
From Surmodics, Inc.
Via Business Wire
Top 3 Health Care Stocks You'll Regret Missing This Month
Via Benzinga
Surmodics Earnings Analysis: Q1 Recap
Via Benzinga
Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries
From Surmodics, Inc.
Via Business Wire
Deal Dispatch: Clock Ticks On TikTok, Raizen Explores Asset Sale, Investors Urge Walgreens To Go Private
Via Benzinga
Why Surmodics Stock Is Falling On Friday
Via Benzinga
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR
From Surmodics, Inc.
Via Business Wire
Assessing Surmodics: Insights From 5 Financial Analysts
Via Benzinga
Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries
From Surmodics, Inc.
Via Business Wire
Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results
From Surmodics, Inc.
Via Business Wire
Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Surmodics, Inc.
Via Business Wire
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System
From Surmodics, Inc.
Via Business Wire
Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter
From Surmodics, Inc.
Via Business Wire
SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q3 2024
Via InvestorPlace
Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results
From Surmodics, Inc.
Via Business Wire
SURMODICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, SRDX, AGS, VAPO on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SRDX, ATRI on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.
From Surmodics, Inc.
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Marathon Oil Corporation (NYSE – MRO), Atrion Corporation (Nasdaq – ATRI), Surmodics, Inc. (Nasdaq – SRDX), Akili, Inc. (Nasdaq – AKLI)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Marathon Oil Corporation (NYSE – MRO), Atrion Corporation (Nasdaq – ATRI), Surmodics, Inc. (Nasdaq – SRDX), Akili, Inc. (Nasdaq – AKLI)
From Brodsky & Smith LLC
Via GlobeNewswire

Frequently Asked Questions

Is Surmodics, Inc. - Common Stock publicly traded?
Yes, Surmodics, Inc. - Common Stock is publicly traded.
What exchange does Surmodics, Inc. - Common Stock trade on?
Surmodics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Surmodics, Inc. - Common Stock?
The ticker symbol for Surmodics, Inc. - Common Stock is SRDX on the Nasdaq Stock Market
What is the current price of Surmodics, Inc. - Common Stock?
The current price of Surmodics, Inc. - Common Stock is 27.09
When was Surmodics, Inc. - Common Stock last traded?
The last trade of Surmodics, Inc. - Common Stock was at 05/12/25 04:00 PM ET
What is the market capitalization of Surmodics, Inc. - Common Stock?
The market capitalization of Surmodics, Inc. - Common Stock is 382.89M
How many shares of Surmodics, Inc. - Common Stock are outstanding?
Surmodics, Inc. - Common Stock has 383M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.